Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) Free Cash Flow Yield: 5.57%

Is Medpace Holdings, Inc.’s free cash flow yield high or low?

Medpace Holdings, Inc.'s free cash flow yield of 5.57% is 23% above its 5-year average of 4.51%, near the high end of its 5-year range (3.02%–6.48%).

As of Wednesday, June 17, 2026. 18.90% above its 12-month average of 4.68%.

MEDP Free Cash Flow Yield Chart

MEDP Free Cash Flow Yield
5.57%-4.30% 1Y
Zoom

MEDP Average Free Cash Flow Yield Chart

MEDP Current vs Average Free Cash Flow Yield Chart

MEDP Free Cash Flow Yield Metrics

FREE CASH FLOW YIELD

5.57%

FREE CASH FLOW YIELD AVG TTM

4.68%

FREE CASH FLOW YIELD AVG 3Y

4.57%

FREE CASH FLOW YIELD AVG 5Y

4.51%

FREE CASH FLOW YIELD AVG 10Y

5.07%

FREE CASH FLOW YIELD AVG 15Y

N/A

FREE CASH FLOW YIELD AVG 20Y

N/A

CURRENT VS TTM AVG

+18.90%

CURRENT VS 3Y AVG

+21.90%

CURRENT VS 5Y AVG

+23.42%

CURRENT VS 10Y AVG

+9.88%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MEDP Competitors' Free Cash Flow Yield

NAMEMARKET CAPFREE CASH FLOW YIELDTTM3Y5Y
Medpace Holdings, Inc. (MEDP)$13.05B5.57%4.68%4.57%4.51%
The Cooper Companies, Inc. (COO)vs ›$13.14B4.34%3.04%1.91%2.24%
Solventum Corporation (SOLV)vs ›$12.91BN/A2.46%7.43%7.43%
Align Technology, Inc. (ALGN)vs ›$12.86B5.34%5.42%3.79%3.05%
DaVita Inc. (DVA)vs ›$13.46B10.37%12.85%12.07%12.08%
Revvity, Inc. (RVTY)vs ›$10.91B4.51%4.59%3.05%4.01%
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B5.60%5.84%5.45%8.51%
Baxter International Inc. (BAX)vs ›$10.19B6.78%3.22%3.93%3.75%
Hologic, Inc. (HOLX)vs ›$16.97B5.82%6.28%5.68%7.87%
Charles River Laboratories International, Inc. (CRL)vs ›$8.90B4.33%6.27%5.04%4.15%

Yield Comparison

FCF Yield

5.57%

Earnings Yield

3.48%

Dividend Yield

N/A

Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100

How FCF Yield is used:

  • Shows free cash flow after capital expenditures relative to market cap
  • Can be compared with earnings yield and dividend yield
  • Can be compared with the company's historical range
  • Can be compared with peers that report positive free cash flow

FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.

Medpace Holdings, Inc. Free Cash Flow Yield Formula & Definition

FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medpace Holdings, Inc. Free Cash Flow Yield FAQ

What is the free cash flow yield for Medpace Holdings, Inc. (MEDP)?
The free cash flow yield for MEDP stock is 5.57%.
Is Medpace Holdings, Inc.'s free cash flow yield high or low?
Medpace Holdings, Inc.'s free cash flow yield of 5.57% is 23% above its 5-year average of 4.51%, near the high end of its 5-year range (3.02%–6.48%).
What is the TTM average free cash flow yield for Medpace Holdings, Inc. (MEDP)?
The TTM average free cash flow yield for MEDP stock is 4.68%.
What is the 3Y average free cash flow yield for Medpace Holdings, Inc. (MEDP)?
The 3Y average free cash flow yield for MEDP stock is 4.57%.
What is the 5Y average free cash flow yield for Medpace Holdings, Inc. (MEDP)?
The 5Y average free cash flow yield for MEDP stock is 4.51%.
What is the 10Y average free cash flow yield for Medpace Holdings, Inc. (MEDP)?
The 10Y average free cash flow yield for MEDP stock is 5.07%.

Medpace Holdings, Inc. Free Cash Flow Yield History

DATEFREE CASH FLOW YIELD
2026-06-175.57%
2026-06-165.52%
2026-06-155.45%
2026-06-125.45%
2026-06-115.36%
2026-06-105.47%
2026-06-095.46%
2026-06-085.56%
2026-06-055.61%
2026-06-045.55%
2026-06-035.65%
2026-06-025.72%
2026-06-015.64%
2026-05-295.70%
2026-05-285.69%
2026-05-275.95%
2026-05-265.94%
2026-05-225.89%
2026-05-215.92%
2026-05-206.04%
2026-05-196.07%
2026-05-186.06%
2026-05-156.13%
2026-05-146.08%
2026-05-136.01%
2026-05-126.07%
2026-05-116.11%
2026-05-086.01%
2026-05-075.94%
2026-05-065.97%
2026-05-055.92%
2026-05-046.11%
2026-05-016.10%
2026-04-306.09%
2026-04-296.16%
2026-04-286.22%
2026-04-276.05%
2026-04-246.20%
2026-04-236.48%
2026-04-224.81%
2026-04-214.75%
2026-04-204.63%
2026-04-174.70%
2026-04-164.75%
2026-04-154.72%
2026-04-144.71%
2026-04-134.88%
2026-04-104.96%
2026-04-094.88%
2026-04-084.70%
2026-04-074.81%
2026-04-064.93%
2026-04-024.91%
2026-04-015.00%
2026-03-315.09%
2026-03-305.32%
2026-03-275.42%
2026-03-265.24%
2026-03-255.24%
2026-03-245.31%
2026-03-235.36%
2026-03-205.41%
2026-03-195.31%
2026-03-185.38%
2026-03-175.38%
2026-03-165.39%
2026-03-135.43%
2026-03-125.51%
2026-03-115.12%
2026-03-105.24%
2026-03-095.11%
2026-03-065.20%
2026-03-055.21%
2026-03-045.25%
2026-03-035.26%
2026-03-025.35%
2026-02-275.42%
2026-02-265.47%
2026-02-255.59%
2026-02-245.53%
2026-02-235.50%
2026-02-205.39%
2026-02-195.48%
2026-02-185.49%
2026-02-175.71%
2026-02-135.72%
2026-02-125.88%
2026-02-115.77%
2026-02-105.49%
2026-02-094.47%
2026-02-064.37%
2026-02-054.37%
2026-02-044.22%
2026-02-034.16%
2026-02-024.03%
2026-01-304.07%
2026-01-293.99%
2026-01-283.96%
2026-01-273.93%
2026-01-263.93%
2026-01-234.03%
2026-01-223.91%
2026-01-213.82%
2026-01-203.93%
2026-01-163.88%
2026-01-153.83%
2026-01-143.84%
2026-01-133.89%
2026-01-123.95%
2026-01-093.98%
2026-01-083.95%
2026-01-073.86%
2026-01-063.89%
2026-01-054.04%
2026-01-024.15%
2025-12-314.22%
2025-12-304.16%
2025-12-294.15%
2025-12-264.17%
2025-12-244.14%
2025-12-234.16%
2025-12-224.14%
2025-12-194.17%
2025-12-184.23%
2025-12-174.25%
2025-12-164.24%
2025-12-154.24%
2025-12-124.24%
2025-12-114.18%
2025-12-104.22%
2025-12-094.35%
2025-12-084.31%
2025-12-054.32%
2025-12-044.35%
2025-12-034.11%
2025-12-024.06%
2025-12-014.03%
2025-11-284.00%
2025-11-263.90%
2025-11-253.87%
2025-11-243.83%
2025-11-214.00%
2025-11-204.04%
2025-11-194.00%
2025-11-184.01%
2025-11-174.04%
2025-11-144.01%
2025-11-134.00%
2025-11-123.96%
2025-11-113.93%
2025-11-103.94%
2025-11-074.02%
2025-11-064.00%
2025-11-053.95%
2025-11-043.98%
2025-11-033.99%
2025-10-314.05%
2025-10-304.08%
2025-10-294.05%
2025-10-284.08%
2025-10-273.97%
2025-10-243.91%
2025-10-233.97%
2025-10-223.52%
2025-10-213.52%
2025-10-203.53%
2025-10-173.64%
2025-10-163.69%
2025-10-153.74%
2025-10-143.72%
2025-10-133.64%
2025-10-103.83%
2025-10-093.71%
2025-10-083.62%
2025-10-073.61%
2025-10-063.62%
2025-10-033.61%
2025-10-023.59%
2025-10-013.53%
2025-09-303.74%
2025-09-293.84%
2025-09-263.87%
2025-09-253.94%
2025-09-243.87%
2025-09-233.87%
2025-09-223.86%
2025-09-193.86%
2025-09-183.83%
2025-09-173.86%
2025-09-163.92%
2025-09-153.87%
2025-09-123.92%
2025-09-113.86%
2025-09-104.03%
2025-09-093.96%
2025-09-083.91%
2025-09-053.95%
2025-09-043.99%
2025-09-033.99%
2025-09-024.06%
2025-08-294.04%
2025-08-284.07%
2025-08-274.06%
2025-08-264.10%
2025-08-254.12%
2025-08-224.15%
2025-08-214.24%
2025-08-204.13%
2025-08-194.16%
2025-08-184.15%
2025-08-154.20%
2025-08-144.19%
2025-08-134.11%
2025-08-124.19%
2025-08-114.27%
2025-08-084.42%
2025-08-074.48%
2025-08-064.47%
2025-08-054.41%
2025-08-044.44%
2025-08-014.54%
2025-07-314.50%
2025-07-304.39%
2025-07-294.29%
2025-07-284.24%
2025-07-254.30%
2025-07-244.22%
2025-07-234.39%
2025-07-224.02%
2025-07-215.61%
2025-07-185.56%
2025-07-175.43%
2025-07-165.51%
2025-07-155.55%
2025-07-145.41%
2025-07-115.36%
2025-07-105.28%
2025-07-095.40%
2025-07-085.38%
2025-07-075.44%
2025-07-035.39%
2025-07-025.32%
2025-07-015.40%
2025-06-305.52%
2025-06-275.58%
2025-06-265.65%
2025-06-255.57%
2025-06-245.50%
2025-06-235.62%
2025-06-205.61%
2025-06-185.73%
2025-06-175.82%
2025-06-165.76%
2025-06-135.81%
2025-06-125.70%
2025-06-115.74%
2025-06-105.67%
2025-06-095.81%
2025-06-065.85%
2025-06-055.91%

Showing the most recent 260 of 2,476 data points. The chart above shows the full history.

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle